董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Gail M. Farfel | -- | Director | -- | 未披露 | 未持股 | 2020-03-05 |
| Judith J. Robertson | -- | Director | -- | 未披露 | 未持股 | 2020-03-05 |
| James E. Brown | 男 | President, Chief Executive Officer and Director | 63 | 90.17万美元 | 未持股 | 2020-03-05 |
| Simon X. Benito | 男 | Director | 80 | 12.90万美元 | 未持股 | 2020-03-05 |
| Terrence F. Blaschke | 男 | Director | 82 | 10.45万美元 | 未持股 | 2020-03-05 |
| Armand P. Neukermans | 男 | Director | 84 | 12.20万美元 | 未持股 | 2020-03-05 |
| David R. Hoffmann | 男 | Director, Chairman of the Board | 80 | 13.54万美元 | 未持股 | 2020-03-05 |
| Jon S. Saxe | 男 | Director | 88 | 11.50万美元 | 未持股 | 2020-03-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Judy R. Joice | 女 | Senior Vice President, Operations and Corporate Quality Assurance | 63 | 45.00万美元 | 未持股 | 2020-03-05 |
| Michael H. Arenberg | 男 | Chief Financial Officer | 50 | 未披露 | 未持股 | 2020-03-05 |
| James E. Brown | 男 | President, Chief Executive Officer and Director | 63 | 90.17万美元 | 未持股 | 2020-03-05 |
董事简历
中英对照 | 中文 | 英文- Gail M. Farfel
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- Judith J. Robertson
-
暂无中文简介
暂无英文简介 -
暂无中文简介
- 暂无英文简介
- James E. Brown
-
James E. Brown，1998年2月联合创立DURECT，1998年6月起担任总裁、首席执行官和董事。他此前在ALZA Corporation工作，1995年6月至1998年6月，担任生物制药和移植研发部副总裁。此前，他在制药公司Syntex Corporation担任多个职位，包括1994年5月至1995年5月担任业务发展董事，1992年4月至1995年5月担任开发研究合资企业主管，1985年10月至1992年3月在Syntex 研发部担任项目主管。他获有San Jose State University的学位，以及the University of California, Davis的兽医学博士学位，并在此完成了药理学和毒理学的博士后工作。
James E. Brown, co-founded DURECT in February 1998 and has served as our President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995 Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. Doctor of Veterinary Medicine from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology. - James E. Brown，1998年2月联合创立DURECT，1998年6月起担任总裁、首席执行官和董事。他此前在ALZA Corporation工作，1995年6月至1998年6月，担任生物制药和移植研发部副总裁。此前，他在制药公司Syntex Corporation担任多个职位，包括1994年5月至1995年5月担任业务发展董事，1992年4月至1995年5月担任开发研究合资企业主管，1985年10月至1992年3月在Syntex 研发部担任项目主管。他获有San Jose State University的学位，以及the University of California, Davis的兽医学博士学位，并在此完成了药理学和毒理学的博士后工作。
- James E. Brown, co-founded DURECT in February 1998 and has served as our President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995 Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. Doctor of Veterinary Medicine from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.
- Simon X. Benito
-
Simon X. Benito，自2003年12月以来一直在Inovio Pharmaceuticals, Inc.的董事会任职，给Inovio Pharmaceuticals, Inc.带来了常规的会计和金融培训和专业知识、丰富的上市公司董事会经验、医疗行业高级管理经验和重要的业界关系网。在退休之前，Benito先生曾有过成功、丰富的服务一些跨国公司的高级管理职位的职业生涯，包括在Merck公司的25年。他最近的职位包括Merck 疫苗部的高级副总裁、Merck-Medco Managed Care的副执行总裁、Merck Human Health（日本）的执行董事和副总裁。另外，他曾是英国（England）特许会计师协会的30年的会员一直到1999年退休。自2005年4月以来，他曾是一个公开上市的特种制药公司- DURECT的董事。
Simon X. Benito,Prior to his retirement, Mr. Benito had a successful and extensive career serving several multinational corporations in senior executive positions, including 25 years at Merck & Company, Inc. His most recent positions included Senior Vice President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company. - Simon X. Benito，自2003年12月以来一直在Inovio Pharmaceuticals, Inc.的董事会任职，给Inovio Pharmaceuticals, Inc.带来了常规的会计和金融培训和专业知识、丰富的上市公司董事会经验、医疗行业高级管理经验和重要的业界关系网。在退休之前，Benito先生曾有过成功、丰富的服务一些跨国公司的高级管理职位的职业生涯，包括在Merck公司的25年。他最近的职位包括Merck 疫苗部的高级副总裁、Merck-Medco Managed Care的副执行总裁、Merck Human Health（日本）的执行董事和副总裁。另外，他曾是英国（England）特许会计师协会的30年的会员一直到1999年退休。自2005年4月以来，他曾是一个公开上市的特种制药公司- DURECT的董事。
- Simon X. Benito,Prior to his retirement, Mr. Benito had a successful and extensive career serving several multinational corporations in senior executive positions, including 25 years at Merck & Company, Inc. His most recent positions included Senior Vice President, Merck Vaccine Division; Executive Vice President, Merck-Medco Managed Care; and Executive Director and Vice President, Merck Human Health, Japan. In addition, Mr. Benito was a Fellow of the Institute of Chartered Accountants in England and Wales for over 30 years until his retirement in 1999. Since April 2005, Mr. Benito has served as a director of DURECT Corporation, a publicly traded specialty pharmaceutical company.
- Terrence F. Blaschke
-
Terrence F. Blaschke，2006年12月起担任董事。他1974年起担任Stanford University 的教员，也是 Stanford University School of Medicine的医药和分子药理学荣誉教授。他现在是the Bill and Melinda Gates Foundation的全球健康发现和转化科学的高级项目官。他2000至2002年在Pharsight Corporation担任方法论和科学部副总裁。他担任独立顾问，和多家领先的制药和生物科技公司打交道。他是Therapeutic Discovery Corporation and Crescendo Pharmaceuticals的前董事会成员，两家都是上市公司。他还在美国食品药品监管局（FDA）担任特别政府雇员，担任FDA的基因药物咨询委员会主席。
Terrence F. Blaschke, M.D. has served as a director since December 2006. Dr. Blaschke has served on the faculty of Stanford University since 1974 and is Professor of Medicine and Molecular Pharmacology Emeritus at the Stanford University School of Medicine. From 2012 to January 2016 he was a senior program officer, Global Health Discovery and Translational Science at the Bill and Melinda Gates Foundation. Dr. Blaschke held the position of Vice President of Methodology and Science at Pharsight Corporation from 2000 to 2002. Dr. Blaschke has served as an independent consultant working with a number of leading pharmaceutical and biotechnology companies. Dr. Blaschke was formerly a board member of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals, two publicly-traded companies. He has also worked as a special government employee for the U.S. Food and Drug Administration (“FDA”) and has served as the chairman of the FDA’s Generic Drugs Advisory Committee. - Terrence F. Blaschke，2006年12月起担任董事。他1974年起担任Stanford University 的教员，也是 Stanford University School of Medicine的医药和分子药理学荣誉教授。他现在是the Bill and Melinda Gates Foundation的全球健康发现和转化科学的高级项目官。他2000至2002年在Pharsight Corporation担任方法论和科学部副总裁。他担任独立顾问，和多家领先的制药和生物科技公司打交道。他是Therapeutic Discovery Corporation and Crescendo Pharmaceuticals的前董事会成员，两家都是上市公司。他还在美国食品药品监管局（FDA）担任特别政府雇员，担任FDA的基因药物咨询委员会主席。
- Terrence F. Blaschke, M.D. has served as a director since December 2006. Dr. Blaschke has served on the faculty of Stanford University since 1974 and is Professor of Medicine and Molecular Pharmacology Emeritus at the Stanford University School of Medicine. From 2012 to January 2016 he was a senior program officer, Global Health Discovery and Translational Science at the Bill and Melinda Gates Foundation. Dr. Blaschke held the position of Vice President of Methodology and Science at Pharsight Corporation from 2000 to 2002. Dr. Blaschke has served as an independent consultant working with a number of leading pharmaceutical and biotechnology companies. Dr. Blaschke was formerly a board member of Therapeutic Discovery Corporation and Crescendo Pharmaceuticals, two publicly-traded companies. He has also worked as a special government employee for the U.S. Food and Drug Administration (“FDA”) and has served as the chairman of the FDA’s Generic Drugs Advisory Committee.
- Armand P. Neukermans
-
Armand P. Neukermans，2001年3月起担任董事。他1996年12月创立了 Xros, Inc.。Xros2000年3月被Nortel Networks收购，成为其一个部门。他在Xros担任主席和首席技术官职位直至2002年6月。1993年10月，他创立Adagio Associates，这是一家咨询公司，关注仪表、度量和微制造等领域，现任其总裁。1992至1993年，他担任Teknekron TSDC的系统开发副总裁。1985至1992年，他在Tencor Instruments担任多个职位，包括副总裁和首席技术官。1973至1985年，他在Hewlett Packard Company, HP Labs担任多个职位，包括部门经理。他获有Louvain University的机械和电子工程学位，Arizona State University的电子工程硕士学位，以及Stanford University的应用物理学博士学位。他2001年被提名为年度硅谷投资家。
Armand P. Neukermans, Ph.D. has served as a Director since March 2001. Dr. Neukermans founded Xros, Inc. in December 1996. Xros was acquired by and became a division of Nortel Networks in March 2000. Throughout and until June 2002 Dr. Neukermans held the position of Chairman and Chief Technical Officer at Xros. In October 1993 Dr. Neukermans founded Adagio Associates, a consulting firm in the area of instrumentation, metrology and microfabrication and currently serves as its President. From 1992 to 1993 Dr. Neukermans was Vice President, Systems Development at Teknekron TSDC. Between 1985 and 1992 Dr. Neukermans held various positions at Tencor Instruments including Vice President and Chief Technical Officer. From 1973 to 1985 Dr. Neukermans held various positions at Hewlett Packard Company, HP Labs, including Department Manager. Dr. Neukermans holds an Engineer’s Degree in Mechanical and Electrical Engineering from Louvain University, an M.S. in Electrical Engineering from Arizona State University and a Ph.D. in Applied Physics from Stanford University. Dr. Neukermans was named Silicon Valley Inventor of the Year in 2001. - Armand P. Neukermans，2001年3月起担任董事。他1996年12月创立了 Xros, Inc.。Xros2000年3月被Nortel Networks收购，成为其一个部门。他在Xros担任主席和首席技术官职位直至2002年6月。1993年10月，他创立Adagio Associates，这是一家咨询公司，关注仪表、度量和微制造等领域，现任其总裁。1992至1993年，他担任Teknekron TSDC的系统开发副总裁。1985至1992年，他在Tencor Instruments担任多个职位，包括副总裁和首席技术官。1973至1985年，他在Hewlett Packard Company, HP Labs担任多个职位，包括部门经理。他获有Louvain University的机械和电子工程学位，Arizona State University的电子工程硕士学位，以及Stanford University的应用物理学博士学位。他2001年被提名为年度硅谷投资家。
- Armand P. Neukermans, Ph.D. has served as a Director since March 2001. Dr. Neukermans founded Xros, Inc. in December 1996. Xros was acquired by and became a division of Nortel Networks in March 2000. Throughout and until June 2002 Dr. Neukermans held the position of Chairman and Chief Technical Officer at Xros. In October 1993 Dr. Neukermans founded Adagio Associates, a consulting firm in the area of instrumentation, metrology and microfabrication and currently serves as its President. From 1992 to 1993 Dr. Neukermans was Vice President, Systems Development at Teknekron TSDC. Between 1985 and 1992 Dr. Neukermans held various positions at Tencor Instruments including Vice President and Chief Technical Officer. From 1973 to 1985 Dr. Neukermans held various positions at Hewlett Packard Company, HP Labs, including Department Manager. Dr. Neukermans holds an Engineer’s Degree in Mechanical and Electrical Engineering from Louvain University, an M.S. in Electrical Engineering from Arizona State University and a Ph.D. in Applied Physics from Stanford University. Dr. Neukermans was named Silicon Valley Inventor of the Year in 2001.
- David R. Hoffmann
-
David R. Hoffmann，2002年12月起担任董事，2010年12月起担任首席独立董事。他从ALZA Corporation（现Johnson & Johnson成员公司）退休，1992至2002年10月退休前担任副总裁和财务主管；1982至1992年担任财务副总裁；1976至1982年担任会计和财务主管。他现在是专注于游轮旅游、财务及福利咨询大型集团公司Hoffmann Associates的首席执行官。他获有the University of Colorado的工商管理学位。他现在是生物科技公司Threshold Pharmaceuticals的董事会成员和审计委员会主席。
David R. Hoffmann,has been a director of the Company since August 2017, effective as of the Merger, and served as a director of Pre-Merger Threshold since April 2007. Since 2002, Mr. Hoffmann has served as the Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. Mr. Hoffmann holds a B.S. in Business Administration from the University of Colorado. - David R. Hoffmann，2002年12月起担任董事，2010年12月起担任首席独立董事。他从ALZA Corporation（现Johnson & Johnson成员公司）退休，1992至2002年10月退休前担任副总裁和财务主管；1982至1992年担任财务副总裁；1976至1982年担任会计和财务主管。他现在是专注于游轮旅游、财务及福利咨询大型集团公司Hoffmann Associates的首席执行官。他获有the University of Colorado的工商管理学位。他现在是生物科技公司Threshold Pharmaceuticals的董事会成员和审计委员会主席。
- David R. Hoffmann,has been a director of the Company since August 2017, effective as of the Merger, and served as a director of Pre-Merger Threshold since April 2007. Since 2002, Mr. Hoffmann has served as the Chief Executive Officer of Hoffmann Associates, a multi-group company specializing in cruise travel and financial and benefit consulting. Mr. Hoffmann holds a B.S. in Business Administration from the University of Colorado.
- Jon S. Saxe
-
Jon S. Saxe，自2000年起担任Vistagen Therapeutics, Inc.董事会主席，先是担任加利福尼亚州公司Vistastem，Inc.（前身为Vistagen Therapeutics, Inc.）（Vistastem）的董事会主席，后在公司与Vistastem于2011年5月11日合并后担任Vistagen Therapeutics, Inc.董事会主席，此时Vistastem成为公司的全资子公司（合并）。还担任Vistagen Therapeutics, Inc.审计委员会主席。Saxe先生是已退休的总裁，并于1989年至2008年担任PDL生物制药的董事。1989年至1993年，他是Synergen，Inc.（已被安进收购）的总裁、首席执行官和董事。Saxe先生曾于1984年至1989年担任Hoffmann-Roche的许可和企业发展副总裁，并于1978年至1989年担任Hoffmann-Roche的专利法主管。Saxe先生目前是Kyto Technology and Life Science的首席董事，还担任另外六家私营生命科学公司的董事，这些公司分别是Achelios、Arbor Vita Corporation、Aether，Inc.、Arcuo Medical，LLC、Trellis Bioscience，Inc.和Epalex Corporation。Saxe先生还曾担任其他生物技术和制药公司的董事，包括ID Biomedical（被葛兰素史克收购）、Sciele Pharmaceuticals，Inc.（被Shionogi收购）、Amalyte（被Kemin Industries收购）、Cell Pathways（被OSI Pharmaceuticals收购）、Lumos Pharma, Inc.（与New Link Genetics合并）和其他公司，包括公共和私营部门。Saxe先生拥有卡内基-梅隆大学的理学学士学位、乔治华盛顿大学的法学博士学位和纽约大学的法学硕士学位。
Jon S. Saxe,has served as a director on Vistagen Therapeutics, Inc. Board since 2000, and served as Chair of Vistagen Therapeutics, Inc. Board until October 2023. He currently serves as the Chair of Vistagen Therapeutics, Inc. Audit Committee. Mr. Saxe is the retired President and was a director of PDL BioPharma from 1989 to 2008. From 1989 to 1993, he was President, Chief Executive Officer and a director of Synergen, Inc. (acquired by Amgen). Mr. Saxe served as Vice President, Licensing & Corporate Development for Hoffmann-Roche from 1984 through 1989, and Head of Patent Law for Hoffmann-Roche from 1978 through 1989. Mr. Saxe currently is the lead director of K2x Technology and Life Sciences, is Chair of the board of directors of Epalex Corporation, and serves as a director of five additional private life science companies, Aether, Inc., Achelios Therapeutics, Inc., Arbor Vita Corporation, NuvOx Pharma, LLC and Trellis Bioscience, Inc. In addition, Mr. Saxe serves as a board observer of InGeneron, Inc. and Renexxion, Inc. Mr. Saxe has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics) and other companies, both public and private. Mr. Saxe has a B.S.Ch.E. from Carnegie-Mellon University, a J.D. degree from George Washington University and an LL.M. degree from New York University. In addition, Mr. Saxe has a Certificate in Management from Fuqua School of Business, Duke University. - Jon S. Saxe，自2000年起担任Vistagen Therapeutics, Inc.董事会主席，先是担任加利福尼亚州公司Vistastem，Inc.（前身为Vistagen Therapeutics, Inc.）（Vistastem）的董事会主席，后在公司与Vistastem于2011年5月11日合并后担任Vistagen Therapeutics, Inc.董事会主席，此时Vistastem成为公司的全资子公司（合并）。还担任Vistagen Therapeutics, Inc.审计委员会主席。Saxe先生是已退休的总裁，并于1989年至2008年担任PDL生物制药的董事。1989年至1993年，他是Synergen，Inc.（已被安进收购）的总裁、首席执行官和董事。Saxe先生曾于1984年至1989年担任Hoffmann-Roche的许可和企业发展副总裁，并于1978年至1989年担任Hoffmann-Roche的专利法主管。Saxe先生目前是Kyto Technology and Life Science的首席董事，还担任另外六家私营生命科学公司的董事，这些公司分别是Achelios、Arbor Vita Corporation、Aether，Inc.、Arcuo Medical，LLC、Trellis Bioscience，Inc.和Epalex Corporation。Saxe先生还曾担任其他生物技术和制药公司的董事，包括ID Biomedical（被葛兰素史克收购）、Sciele Pharmaceuticals，Inc.（被Shionogi收购）、Amalyte（被Kemin Industries收购）、Cell Pathways（被OSI Pharmaceuticals收购）、Lumos Pharma, Inc.（与New Link Genetics合并）和其他公司，包括公共和私营部门。Saxe先生拥有卡内基-梅隆大学的理学学士学位、乔治华盛顿大学的法学博士学位和纽约大学的法学硕士学位。
- Jon S. Saxe,has served as a director on Vistagen Therapeutics, Inc. Board since 2000, and served as Chair of Vistagen Therapeutics, Inc. Board until October 2023. He currently serves as the Chair of Vistagen Therapeutics, Inc. Audit Committee. Mr. Saxe is the retired President and was a director of PDL BioPharma from 1989 to 2008. From 1989 to 1993, he was President, Chief Executive Officer and a director of Synergen, Inc. (acquired by Amgen). Mr. Saxe served as Vice President, Licensing & Corporate Development for Hoffmann-Roche from 1984 through 1989, and Head of Patent Law for Hoffmann-Roche from 1978 through 1989. Mr. Saxe currently is the lead director of K2x Technology and Life Sciences, is Chair of the board of directors of Epalex Corporation, and serves as a director of five additional private life science companies, Aether, Inc., Achelios Therapeutics, Inc., Arbor Vita Corporation, NuvOx Pharma, LLC and Trellis Bioscience, Inc. In addition, Mr. Saxe serves as a board observer of InGeneron, Inc. and Renexxion, Inc. Mr. Saxe has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics) and other companies, both public and private. Mr. Saxe has a B.S.Ch.E. from Carnegie-Mellon University, a J.D. degree from George Washington University and an LL.M. degree from New York University. In addition, Mr. Saxe has a Certificate in Management from Fuqua School of Business, Duke University.
高管简历
中英对照 | 中文 | 英文- Judy R. Joice
Judy R. Joice，2014年3月起一直担任我们的运营和企业质量保证高级副总裁，2011年4月以来担任运营和企业质量保证副总裁。此前，2008年7月起，她担任企业质量保证副总裁；从2007年7月到2008年7月担任质量保证执行总监。她拥有超过25年医药行业的经验，在Nektar Therapeutics，、Oread、 Roche Pharmaceuticals和Syntex Research工作过。在她的职业生涯中，她在CMC开发活动方面拥有广泛经验，包括新型辅料、新化学实体、设备和组合产品。她曾开发、实施和管理公司范围内的质量系统和合规职能各个方面，从药物开发到商业制造。Joice女士从位于海沃德的加利福尼亚州立大学获得化学学士学位。
Judy R. Joice has served as our Senior Vice President, Operations and Corporate Quality Assurance since March 2014 and as our Vice President, Operations and Corporate Quality Assurance since April 2011. Previously, Ms. Joice served as our Vice President, Corporate Quality Assurance since July 2008 and as our Executive Director, Quality Assurance from July 2007 to July 2008. She has over 25 years’ experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread, Roche Pharmaceuticals, and Syntex Research. During her career, Ms. Joice has gained broad experience in CMC development activities including novel excipients, new chemical entities, devices, and combination products. She has developed, implemented and managed all aspects of company-wide quality systems and compliance functions, ranging from drug development through commercial manufacturing. Ms. Joice has a B.S. in Chemistry from California State University, Hayward.- Judy R. Joice，2014年3月起一直担任我们的运营和企业质量保证高级副总裁，2011年4月以来担任运营和企业质量保证副总裁。此前，2008年7月起，她担任企业质量保证副总裁；从2007年7月到2008年7月担任质量保证执行总监。她拥有超过25年医药行业的经验，在Nektar Therapeutics，、Oread、 Roche Pharmaceuticals和Syntex Research工作过。在她的职业生涯中，她在CMC开发活动方面拥有广泛经验，包括新型辅料、新化学实体、设备和组合产品。她曾开发、实施和管理公司范围内的质量系统和合规职能各个方面，从药物开发到商业制造。Joice女士从位于海沃德的加利福尼亚州立大学获得化学学士学位。
- Judy R. Joice has served as our Senior Vice President, Operations and Corporate Quality Assurance since March 2014 and as our Vice President, Operations and Corporate Quality Assurance since April 2011. Previously, Ms. Joice served as our Vice President, Corporate Quality Assurance since July 2008 and as our Executive Director, Quality Assurance from July 2007 to July 2008. She has over 25 years’ experience in the pharmaceutical industry with such companies as Nektar Therapeutics, Oread, Roche Pharmaceuticals, and Syntex Research. During her career, Ms. Joice has gained broad experience in CMC development activities including novel excipients, new chemical entities, devices, and combination products. She has developed, implemented and managed all aspects of company-wide quality systems and compliance functions, ranging from drug development through commercial manufacturing. Ms. Joice has a B.S. in Chemistry from California State University, Hayward.
- Michael H. Arenberg
MichaelH.Arenberg被任命为首席财务官，于2018年10月生效。Arenberg先生自1999年以来一直在Durect公司任职，最近担任公司和业务发展高级副总裁，，在那里他谈判并完成了50多项合作，包括几项重要的许可证交易。Arenberg先生在科罗拉多大学（University of Colorado）获得本科学位，在丹佛大学（University of Denver）获得法律学位，在圣克拉拉大学（Santa Clara University）利维商学院（Leavy School of Business）获得工商管理硕士学位。
Michael H. Arenberg was appointed Chief Financial Officer effective October 2018. Mr. Arenberg has been with DURECT since 1999 most recently serving as Senior Vice President, Corporate and Business Development, where he negotiated and closed over 50 collaborations, including several important in-licensing transactions. Mr. Arenberg earned his undergraduate degree from the University of Colorado, his law degree from the University of Denver, and his MBA from the Leavy School of Business at Santa Clara University.- MichaelH.Arenberg被任命为首席财务官，于2018年10月生效。Arenberg先生自1999年以来一直在Durect公司任职，最近担任公司和业务发展高级副总裁，，在那里他谈判并完成了50多项合作，包括几项重要的许可证交易。Arenberg先生在科罗拉多大学（University of Colorado）获得本科学位，在丹佛大学（University of Denver）获得法律学位，在圣克拉拉大学（Santa Clara University）利维商学院（Leavy School of Business）获得工商管理硕士学位。
- Michael H. Arenberg was appointed Chief Financial Officer effective October 2018. Mr. Arenberg has been with DURECT since 1999 most recently serving as Senior Vice President, Corporate and Business Development, where he negotiated and closed over 50 collaborations, including several important in-licensing transactions. Mr. Arenberg earned his undergraduate degree from the University of Colorado, his law degree from the University of Denver, and his MBA from the Leavy School of Business at Santa Clara University.
- James E. Brown
James E. Brown，1998年2月联合创立DURECT，1998年6月起担任总裁、首席执行官和董事。他此前在ALZA Corporation工作，1995年6月至1998年6月，担任生物制药和移植研发部副总裁。此前，他在制药公司Syntex Corporation担任多个职位，包括1994年5月至1995年5月担任业务发展董事，1992年4月至1995年5月担任开发研究合资企业主管，1985年10月至1992年3月在Syntex 研发部担任项目主管。他获有San Jose State University的学位，以及the University of California, Davis的兽医学博士学位，并在此完成了药理学和毒理学的博士后工作。
James E. Brown, co-founded DURECT in February 1998 and has served as our President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995 Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. Doctor of Veterinary Medicine from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.- James E. Brown，1998年2月联合创立DURECT，1998年6月起担任总裁、首席执行官和董事。他此前在ALZA Corporation工作，1995年6月至1998年6月，担任生物制药和移植研发部副总裁。此前，他在制药公司Syntex Corporation担任多个职位，包括1994年5月至1995年5月担任业务发展董事，1992年4月至1995年5月担任开发研究合资企业主管，1985年10月至1992年3月在Syntex 研发部担任项目主管。他获有San Jose State University的学位，以及the University of California, Davis的兽医学博士学位，并在此完成了药理学和毒理学的博士后工作。
- James E. Brown, co-founded DURECT in February 1998 and has served as our President, Chief Executive Officer and a Director since June 1998. He previously worked at ALZA Corporation as Vice President of Biopharmaceutical and Implant Research and Development from June 1995 to June 1998. Prior to that, Dr. Brown held various positions at Syntex Corporation, a pharmaceutical company, including Director of Business Development from May 1994 to May 1995 Director of Joint Ventures for Discovery Research from April 1992 to May 1995 and held a number of positions including Program Director for Syntex Research and Development from October 1985 to March 1992. Dr. Brown holds a B.A. from San Jose State University and a D.V.M. Doctor of Veterinary Medicine from the University of California, Davis where he also conducted post-graduate work in pharmacology and toxicology.